Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

Zefei Jiang, Yuan Sheng(Changhai Hospital), Xinhong Wu(Jiangnan University), Haibo Wang(Fujian Medical University), Jingfen Wang, Anqin Zhang(Guangdong Province Women and Children Hospital), Huihua Xiong(Tongji Hospital), Helong Zhang(Shanghai International Studies University), Yudong Wu(Anhui Medical University), Jiuwei Cui(Jilin University), Ying Lin(Sun Yat-sen University), Peifen Fu(First Affiliated Hospital Zhejiang University), Xiaohong Wu(Soochow University), Min Yan(Zhengzhou University), Ying Cheng(Jilin Province Tumor Hospital), Jing Cheng(Wuhan Puai Hospital), Xinlan Liu(Yunnan Agricultural University), Tao Sun(Liaoning Cancer Hospital & Institute), Yuee Teng(First Hospital of China Medical University), Jin Yang(Nanjing University of Chinese Medicine), Yongmei Yin(Nanjing Medical University), Aimin Zang, Lilin Chen(First Affiliated Hospital of Xiamen University), Xueli Mo(Peking University Shougang Hospital), Xin Zhou(Qingdao University), Yongsheng Wang(Shandong Tumor Hospital), Qingshan Li(Shanxi University), Qiang Liu(Sun Yat-sen University), Chuan Wang, Cuizhi Geng(Hebei Medical University), Lili Zhang(Guangxi Medical University), Kun Wang(Union Hospital), Shusen Wang(Sun Yat-sen University), Hui Li(Sichuan Cancer Hospital), Xiaojia Wang(Wenzhou Medical University), Qingyuan Zhang(Jiangxi University of Traditional Chinese Medicine), Kangsheng Gu(Anhui Medical University), Yiding Chen(Second Affiliated Hospital of Zhejiang University), Fanfan Li(Anhui University), Jianyun Nie(Kunming Medical University), Gang Sun(Xinjiang Medical University), Yongqiang Zhang, Danmei Pang(First People's Hospital of Foshan), Man Li(Dalian Medical University), Tienan Yi(Xiangyang Central Hospital), Chunwei Xie, Junlan Yang(People's Liberation Army No. 150 Hospital), Jun Qian(First Affiliated Hospital of Bengbu Medical College), Quchang Ouyang(Hunan Cancer Hospital), Yueyin Pan(University of Science and Technology of China)
Nature Medicine
January 1, 2024
10.1038/s41591-023-02677-x
Cited by 121

Related Papers

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k